Movement Alert｜Sanofi Rises 4.59% in Regular Trading, First-in-Class Drug Venglustat Granted FDA Priority Review for Rare Disease-To The Moon - Tiger Brokers Online Investing Community

Movement Alert｜Sanofi Rises 4.59% in Regular Trading, First-in-Class Drug Venglustat Granted FDA Priority Review for Rare Disease

Market Focus06-04 22:06

On June 4, Sanofi rose 4.59% in regular trading, trading at $44.56/share, with trading volume of $27.25 million. The rally was driven by the announcement that its first-in-class drug Venglustat received FDA acceptance and priority review designation for the treatment of Type 3 Gaucher disease.

Specifically, if approved, Venglustat would become the first treatment in the United States targeting progressive neurological manifestations associated with GD3. The FDA has set a target action date of November 25. The acceptance was primarily based on positive results from the Phase 3 LEAP2MONO study, in which Venglustat met both primary endpoints and three out of four key secondary endpoints. Gaucher disease causes abnormal accumulation of sugar-and-fat molecules in the spleen, liver, bone marrow, and lungs, potentially leading to neurological and cognitive challenges.

Additionally, Sanofi recently advanced the clinical application of a first-in-class JAK/ROCK dual-target inhibitor, further expanding its innovative pipeline in hematology and transplantation. Within the Pharmacy sector, broader strength was observed with Eli Lilly up 3.89%, Merck up 4.49%, Novo-Nordisk up 4.56%, and Pfizer up 2.15%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Movement Alert｜Sanofi Rises 4.59% in Regular Trading, First-in-Class Drug Venglustat Granted FDA Priority Review for Rare Disease

Comments